German construction sector still in recession, civil engineering only bright spot
NEW YORK - Danish biotechnology company Genmab A/S (NASDAQ:GMAB) has agreed to acquire Dutch oncology firm Merus N.V. (NASDAQ:MRUS) for $97 per share in an all-cash transaction valued at approximately $8 billion, according to a press release statement.
The acquisition price represents a 41% premium to Merus’ closing share price on September 26, before the announcement. The transaction is expected to close in the first quarter of 2026, pending regulatory approvals.
Merus specializes in developing full-length human bispecific and trispecific antibody therapeutics for cancer treatment. The company’s lead asset, petosemtamab, has received two Breakthrough Therapy Designations from the FDA for head and neck cancer treatment.
The acquisition will integrate Merus’ oncology pipeline into Genmab’s portfolio, leveraging Genmab’s expertise in antibody therapy development and commercialization in oncology.
This deal marks the third acquisition from RTW Biotech Opportunities Ltd’s portfolio this year, following earlier transactions involving Verona and Alcyone. As of August 31, Merus represented 1.18% of RTW Biotech Opportunities’ net asset value.
The announcement comes amid increased merger and acquisition activity in the biotechnology sector, as pharmaceutical companies seek to bolster their pipelines ahead of upcoming patent expirations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.